P1125: CELESTIMO: A PHASE III TRIAL EVALUATING THE EFFICACY AND SAFETY OF MOSUNETUZUMAB PLUS LENALIDOMIDE VERSUS RITUXIMAB PLUS LENALIDOMIDE IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA

• L. Nastoupil,
• F. Morschhauser,
• C. W. Scholz,
• M. Bishton,
• S.-S. Yoon,
• P. Giri,
• M. C. Wei,
• A. Knapp,
• C.-C. Li,
• A. Bottos,
• H. Li,
• E. Purev,
• N. L. Bartlett

Affiliations

L. Nastoupil

1 Emory University, Atlanta, GA, United States of America

F. Morschhauser

2 University of Lille, CHU Lille, Lille, France

C. W. Scholz

3 Vivantes Klinikum am Urban, Berlin, Germany

M. Bishton

4 Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom

S.-S. Yoon

5 Seoul National University Hospital, Seoul, South Korea

P. Giri

6 Royal Adelaide Hospital, Adelaide, Australia

M. C. Wei

7 Genentech, Inc., South San Francisco, CA, United States of America

A. Knapp

8 F. Hoffmann-La Roche Ltd, Basel, Switzerland

C.-C. Li

7 Genentech, Inc., South San Francisco, CA, United States of America

A. Bottos

8 F. Hoffmann-La Roche Ltd, Basel, Switzerland

H. Li

9 Hoffmann-La Roche Ltd, Mississauga, ON, Canada

E. Purev

7 Genentech, Inc., South San Francisco, CA, United States of America

N. L. Bartlett

10 Washington University School of Medicine, St. Louis, United States of America